Precautions
Women who have experienced vaginal bleeding post menopause, certain cancers, stroke, heart attack, blood clotting, or uncontrollable bleeding, and women who are pregnant or allergic to ingredients in estrogen patches should not use an estrogen patch as serious adverse effects may occur. Society and culture
Brand names
Estrogen patches are available in multiple brand names in different countries. Some patches are available with a progestin such as levonorgestrel, norethisterone acetate, or norelgestromin. See also
Pharmacokinetics of estradiol § Transdermal administration
Hormone replacement therapy

References
External links
"Estradiol". Drug Information Portal. U.S. National Library of Medicine. "Estradiol mixture with levonorgestrel". Drug Information Portal. U.S. National Library of Medicine. "Estradiol mixture with norethindrone acetate". Drug Information Portal. U.S. National Library of Medicine.
17q12 microdeletion syndrome, also known as 17q12 deletion syndrome, is a rare chromosomal anomaly caused by the deletion of a small amount of material from a region in the long arm of chromosome 17. It is typified by deletion of the HNF1B gene, resulting in kidney abnormalities and renal cysts and diabetes syndrome. It also has neurocognitive effects, and has been implicated as a genetic factor for autism and schizophrenia. 17q12 microdeletion syndrome is not to be confused with 17q12 microduplication syndrome, caused by the addition of genetic material in the same region from which it is removed in the microdeletion, or 17q21.31 microdeletion syndrome, another name for Koolen–De Vries syndrome. Presentation
17q12 microdeletions have a variable phenotype, ranging from few or no symptoms to severe disability. The condition is thought to be underdiagnosed, and cases with milder phenotypes may not reach clinical attention unless they have an affected child themselves. The most characteristic symptom is renal cysts and diabetes syndrome (RCAD), also known as "type 5 diabetes", which is caused by deletion of the associated HNF1B gene in the region. RCAD is associated with kidney abnormalities and a characteristic form of diabetes that causes atrophy of the pancreas. However, some people with 17q12 microdeletions have normal renal function. RCAD is diagnosed in approximately 40% of people with 17q12 microdeletions, usually prior to age 25, while kidney abnormalities more broadly occur in approximately 85-90%.People with 17q12 microdeletions have a characteristic facial phenotype, albeit a subtle one not usually obvious in daily life.